



(43) International Publication Date 26 April 2001 (26,04,2001)

(10) International Publication Number WO 01/28567 A2

- (51) International Patent Classification7: A61K 31/662, A6IP 19/08
- (21) International Application Number: PCT/US00/28713
- (22) International Filing Date: 17 October 2000 (17.10.2000)
- (25) Filing Language:

(30) Priority Data:

English

(26) Publication Language:

English

(84) Designated States (regional); ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT. BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

- 60/160.019 18 October 1999 (18.10.1999) US
- (71) Applicant (for all designated States except US): THE DOW CHEMICAL COMPANY [US/US]; 2030 Dow Center, Midland, MI 48674 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU. AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU. ID. IL. IN. IS. JP. KE. KG. KR. KZ. LC. I.K. I.R. I.S. I.T. LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, YU, ZA, ZW.
 - CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

Without international search report and to be republished upon receipt of that report.

IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,

- (72) Inventor: and
- (75) Inventor/Applicant (for US only): FRANK, R., Keith [US/US]; 213 Pansy Path, Lake Jackson, TX 77566 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(74) Agent: KARADZIC, Dragan, J.; Intellectual Property, B-1211, 2301 N. Brazosport Boulevard, Freeport, TX 77541 (US).

(54) Title: AMINOALKYLENEPHOSPHONATES FOR TREATMENT OF BONE DISORDERS

(57) Abstract: A method for preventing or minimizing loss f bone mineral in mammals which method comprises administering to a mammal an amount of an aminoalkylenephosph nate which is effective to prevent or minimize loss of bone mineral density. The aminoalkylenephosphonates of the present invention should have at least one R-N(Alk-PO₃H₂), group or at least two RRN-Alk-PO₃H₂ groups wherein R and R can be, same or different, aliphatic or cyclic moiety, and Alk is an alkylene group having from 1 to 4 carbon atoms.